CD30

CD30, conosciuto anche come TNFRSF8, è una proteina di membrana cellulare appartenente alla famiglia dei recettori per i fattori di necrosi tumorale e marker tumorali.

Questo recettore è espresso mediante attivazione, dalle cellule T e B. TRAF2 e TRAF5 possono interagire con questo recettore, e mediare la trasduzione del segnale che porta all'attivazione di NF-κB. Si tratta di un regolatore che promuove l'apoptosi, ed è in grado di limitare il potenziale proliferativo delle cellule CD8 T e quindi proteggere il corpo contro l'autoimmunità. Due varianti di trascrizione tramite splicing alternativo di questo gene che codificano due isoforme della proteina.^[1]

CD30 è associato al linfoma anaplastico a grandi cellule. Viene espresso nel carcinoma embrionale, ma non nel seminoma ed è quindi un indicatore utile per distinguere tra questi tumori delle cellule germinali.^[2] CD30 e CD15 sono espressi in caso di linfoma di Hodgkin.^[3]

Interazioni

[modifica | modifica wikitesto]

CD30 effettua interazioni proteina-proteina con: TRAF5,^[4] TRAF1,^[5] TRAF2.^[4]^[5] and TRAF3.^[5]

Note

[modifica | modifica wikitesto]

^ Entrez Gene: TNFRSF8 tumor necrosis factor receptor superfamily, member 8, su ncbi.nlm.nih.gov.
^ (ZH) Teng LH, Lu DH, Xu QZ, Fu YJ, Yang H, He ZL, [Expression and diagnostic significance of OCT4, CD117 and CD30 in germ cell tumors], in Zhonghua Bing Li Xue Za Zhi, vol. 34, n. 11, 2005, pp. 711–5, PMID 16536313.
^ Gorczyca W, Tsang P, Liu Z, et al., CD30-positive T-cell lymphomas co-expressing CD15: an immunohistochemical analysis, in Int. J. Oncol., vol. 22, n. 2, febbraio 2003, pp. 319–24, PMID 12527929.
^ ^a ^b S Aizawa, Nakano H, Ishida T, Horie R, Nagai M, Ito K, Yagita H, Okumura K, Inoue J, Watanabe T, Tumor necrosis factor receptor-associated factor (TRAF) 5 and TRAF2 are involved in CD30-mediated NFkappaB activation, in J. Biol. Chem., vol. 272, n. 4, Jan. 1997, pp. 2042–5, DOI:10.1074/jbc.272.4.2042, PMID 8999898.
^ ^a ^b ^c S Ansieau, Scheffrahn I, Mosialos G, Brand H, Duyster J, Kaye K, Harada J, Dougall B, Hübinger G, Kieff E, Herrmann F, Leutz A, Gruss H J, Tumor necrosis factor receptor-associated factor (TRAF)-1, TRAF-2, and TRAF-3 interact in vivo with the CD30 cytoplasmic domain; TRAF-2 mediates CD30-induced nuclear factor kappa B activation, in Proc. Natl. Acad. Sci. U.S.A., vol. 93, n. 24, novembre 1996, pp. 14053–8, DOI:10.1073/pnas.93.24.14053, PMC 19493, PMID 8943059.

Bibliografia

[modifica | modifica wikitesto]

Schneider C, Hübinger G, Pleiotropic signal transduction mediated by human CD30: a member of the tumor necrosis factor receptor (TNFR) family., in Leuk. Lymphoma, vol. 43, n. 7, 2003, pp. 1355–66, DOI:10.1080/10428190290033288, PMID 12389614.
Horie R, Higashihara M, Watanabe T, Hodgkin's lymphoma and CD30 signal transduction., in Int. J. Hematol., vol. 77, n. 1, 2003, pp. 37–47, DOI:10.1007/BF02982601, PMID 12568298.
Tarkowski M, Expression and a role of CD30 in regulation of T-cell activity., in Curr. Opin. Hematol., vol. 10, n. 4, 2004, pp. 267–71, DOI:10.1097/00062752-200307000-00003, PMID 12799531.
Granados S, Hwang ST, Roles for CD30 in the biology and treatment of CD30 lymphoproliferative diseases., in J. Invest. Dermatol., vol. 122, n. 6, 2004, pp. 1345–7, DOI:10.1111/j.0022-202X.2004.22616.x, PMID 15175022.
Dürkop H, Latza U, Hummel M, et al., Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's disease., in Cell, vol. 68, n. 3, 1992, pp. 421–7, DOI:10.1016/0092-8674(92)90180-K, PMID 1310894.
Fonatsch C, Latza U, Dürkop H, et al., Assignment of the human CD30 (Ki-1) gene to 1p36., in Genomics, vol. 14, n. 3, 1992, pp. 825–6, DOI:10.1016/S0888-7543(05)80203-4, PMID 1330892.
Josimovic-Alasevic O, Dürkop H, Schwarting R, et al., Ki-1 (CD30) antigen is released by Ki-1-positive tumor cells in vitro and in vivo. I. Partial characterization of soluble Ki-1 antigen and detection of the antigen in cell culture supernatants and in serum by an enzyme-linked immunosorbent assay., in Eur. J. Immunol., vol. 19, n. 1, 1989, pp. 157–62, DOI:10.1002/eji.1830190125, PMID 2537734.
Stein H, Gerdes J, Schwab U, et al., Identification of Hodgkin and Sternberg-reed cells as a unique cell type derived from a newly-detected small-cell population., in Int. J. Cancer, vol. 30, n. 4, 1983, pp. 445–59, DOI:10.1002/ijc.2910300411, PMID 6754630.
Jung W, Krueger S, Renner C, et al., Opposite effects of the CD30 ligand are not due to CD30 mutations: results from cDNA cloning and sequence comparison of the CD30 antigen from different sources., in Mol. Immunol., vol. 31, n. 17, 1995, pp. 1329–34, DOI:10.1016/0161-5890(94)90051-5, PMID 7527901.
Shiota M, Fujimoto J, Semba T, et al., Hyperphosphorylation of a novel 80 kDa protein-tyrosine kinase similar to Ltk in a human Ki-1 lymphoma cell line, AMS3., in Oncogene, vol. 9, n. 6, 1994, pp. 1567–74, PMID 8183550.
Lee SY, Park CG, Choi Y, T cell receptor-dependent cell death of T cell hybridomas mediated by the CD30 cytoplasmic domain in association with tumor necrosis factor receptor-associated factors., in J. Exp. Med., vol. 183, n. 2, 1996, pp. 669–74, DOI:10.1084/jem.183.2.669, PMC 2192463, PMID 8627180.
Gedrich RW, Gilfillan MC, Duckett CS, et al., CD30 contains two binding sites with different specificities for members of the tumor necrosis factor receptor-associated factor family of signal transducing proteins., in J. Biol. Chem., vol. 271, n. 22, 1996, pp. 12852–8, DOI:10.1074/jbc.271.22.12852, PMID 8662842.
Horie R, Ito K, Tatewaki M, et al., A variant CD30 protein lacking extracellular and transmembrane domains is induced in HL-60 by tetradecanoylphorbol acetate and is expressed in alveolar macrophages., in Blood, vol. 88, n. 7, 1996, pp. 2422–32, PMID 8839832.
Ansieau S, Scheffrahn I, Mosialos G, et al., Tumor necrosis factor receptor-associated factor (TRAF)-1, TRAF-2, and TRAF-3 interact in vivo with the CD30 cytoplasmic domain; TRAF-2 mediates CD30-induced nuclear factor kappa B activation., in Proc. Natl. Acad. Sci. U.S.A., vol. 93, n. 24, 1997, pp. 14053–8, DOI:10.1073/pnas.93.24.14053, PMC 19493, PMID 8943059.
Aizawa S, Nakano H, Ishida T, et al., Tumor necrosis factor receptor-associated factor (TRAF) 5 and TRAF2 are involved in CD30-mediated NFkappaB activation., in J. Biol. Chem., vol. 272, n. 4, 1997, pp. 2042–5, DOI:10.1074/jbc.272.4.2042, PMID 8999898.
Lee SY, Lee SY, Choi Y, TRAF-interacting protein (TRIP): a novel component of the tumor necrosis factor receptor (TNFR)- and CD30-TRAF signaling complexes that inhibits TRAF2-mediated NF-kappaB activation., in J. Exp. Med., vol. 185, n. 7, 1997, pp. 1275–85, DOI:10.1084/jem.185.7.1275, PMC 2196258, PMID 9104814.
Boucher LM, Marengère LE, Lu Y, et al., Binding sites of cytoplasmic effectors TRAF1, 2, and 3 on CD30 and other members of the TNF receptor superfamily., in Biochem. Biophys. Res. Commun., vol. 233, n. 3, 1997, pp. 592–600, DOI:10.1006/bbrc.1997.6509, PMID 9168896.
Duckett CS, Thompson CB, CD30-dependent degradation of TRAF2: implications for negative regulation of TRAF signaling and the control of cell survival., in Genes Dev., vol. 11, n. 21, 1997, pp. 2810–21, DOI:10.1101/gad.11.21.2810, PMC 316646, PMID 9353251.
Mizushima S, Fujita M, Ishida T, et al., Cloning and characterization of a cDNA encoding the human homolog of tumor necrosis factor receptor-associated factor 5 (TRAF5)., in Gene, vol. 207, n. 2, 1998, pp. 135–40, DOI:10.1016/S0378-1119(97)00616-1, PMID 9511754.
Kurts C, Carbone FR, Krummel MF, et al., Signalling through CD30 protects against autoimmune diabetes mediated by CD8 T cells., in Nature, vol. 398, n. 6725, 1999, pp. 341–4, DOI:10.1038/18692, PMID 10192335.

Collegamenti esterni

[modifica | modifica wikitesto]

(EN) CD30 Antigens, in Medical Subject Headings (MeSH), National Library of Medicine, 2009.

Portale Biologia: accedi alle voci di Teknopedia che trattano di Biologia

Estratto da "https://it.wikipedia.org/w/index.php?title=CD30&oldid=104442119"

[entrez-1] Entrez Gene: TNFRSF8 tumor necrosis factor receptor superfamily, member 8, su ncbi.nlm.nih.gov.

[2] (ZH) Teng LH, Lu DH, Xu QZ, Fu YJ, Yang H, He ZL, [Expression and diagnostic significance of OCT4, CD117 and CD30 in germ cell tumors], in Zhonghua Bing Li Xue Za Zhi, vol. 34, n. 11, 2005, pp. 711–5, PMID 16536313.

[3] Gorczyca W, Tsang P, Liu Z, et al., CD30-positive T-cell lymphomas co-expressing CD15: an immunohistochemical analysis, in Int. J. Oncol., vol. 22, n. 2, febbraio 2003, pp. 319–24, PMID 12527929.

[pmid8999898-4] S Aizawa, Nakano H, Ishida T, Horie R, Nagai M, Ito K, Yagita H, Okumura K, Inoue J, Watanabe T, Tumor necrosis factor receptor-associated factor (TRAF) 5 and TRAF2 are involved in CD30-mediated NFkappaB activation, in J. Biol. Chem., vol. 272, n. 4, Jan. 1997, pp. 2042–5, DOI:10.1074/jbc.272.4.2042, PMID 8999898.

[pmid8943059-5] S Ansieau, Scheffrahn I, Mosialos G, Brand H, Duyster J, Kaye K, Harada J, Dougall B, Hübinger G, Kieff E, Herrmann F, Leutz A, Gruss H J, Tumor necrosis factor receptor-associated factor (TRAF)-1, TRAF-2, and TRAF-3 interact in vivo with the CD30 cytoplasmic domain; TRAF-2 mediates CD30-induced nuclear factor kappa B activation, in Proc. Natl. Acad. Sci. U.S.A., vol. 93, n. 24, novembre 1996, pp. 14053–8, DOI:10.1073/pnas.93.24.14053, PMC 19493, PMID 8943059.

[1]

[2]

[3]

[4]

[5]

V · D · M Genetica
Materiale genetico	Nucleotidi · Basi azotate · Acidi nucleici (DNA · RNA) · Cromosomi · Genoma
Concetti chiave	Gene · Codice genetico · Allele · Locus · Ereditarietà genetica · Diversità genetica · Mutazione genetica · Variabilità genetica
Campi della genetica	Genetica formale · Genetica molecolare · Genetica delle popolazioni · Genomica · Genetica umana · Epigenetica
Genetisti	Gregor Mendel · Thomas Hunt Morgan · Ronald Fisher · Frederick Griffith · Erwin Chargaff · Barbara McClintock · James Watson · Francis Crick · Rosalind Franklin · Alec Jeffreys